Medicinova Inc
Research Medicinova Inc (MNOV) on Bullrun: market cap USD 77.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMNOV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 77.28M
- Financial periodQ1 2026
- RevenueUSD 186.98K
- Net income-USD 11.72M
- Free cash flow-USD 9.51M
- Gross margin9.0%
Valuation Snapshot
latest market cap is USD 77.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 409.66K | USD 12.00M | -USD 9.81M | 7.6% | -0.24 | USD 30.81M | USD 194.33K | USD 41.59M |
| FY2024 | USD 0 | USD 11.05M | -USD 10.64M | n/a | -0.23 | USD 40.36M | USD 193.77K | USD 52.50M |
| FY2023 | USD 1.00M | USD 8.57M | -USD 7.45M | n/a | -0.17 | USD 51.00M | USD 215.93K | USD 62.38M |
| FY2022 | n/a | -USD 14.07M | -USD 12.92M | n/a | -0.29 | USD 18.51M | USD 183.62K | USD 70.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 77.28M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 64.48M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 103.00M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 73.57M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 100.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 131.44M | n/a | n/a | n/a |
About Medicinova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medicinova Inc's market cap?
Medicinova Inc's market capitalization is USD 77.28M.
What does Medicinova Inc do?
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.